Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14906342 | 0.92 | GPR84 (0.45) | FAAHGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL14906293 | 0.81 | GPR84 (0.62) | FAAHGPR84FFAR1FFAR4LCK | |
| SCHEMBL24711726 | 0.81 | CYP2D6 (0.34) | ALDH1A1 | |
| SCHEMBL26624055 | 0.78 | GPR84 (0.51) | FAAHGPR84FFAR1FFAR4LCK | |
| SCHEMBL14906341 | 0.77 | GPR84 (0.47) | FAAHGPR84FFAR1FFAR4LCK | |
| SCHEMBL14906343 | 0.77 | GPR84 (0.54) | FAAHGPR84FFAR1FFAR4LCK | |
| SCHEMBL14906306 | 0.76 | GPR84 (0.49) | FAAHGPR84FFAR1FFAR4LCK | |
| SCHEMBL14906281 | 0.74 | FFAR1 (0.58) | FAAHGPR84FFAR1FFAR4ALDH1A1 | |
| SCHEMBL15416189 | 0.74 | FAAH (0.68) | FAAHGPR84FFAR1FFAR4 | |
| SCHEMBL14906280 | 0.73 | GPR84 (0.53) | FAAHGPR84FFAR1FFAR4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036333-A9 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-02-08 | — | — | US | disclosed |
| US-20170165290-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-06-15 | — | — | US | disclosed |
| US-9512073-B2 | Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20130158021-A1 | AMINO ACID-, PEPTIDE-AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165290-A1 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | FAAH 1214/4885GPR84 225/4885FFAR1 129/4885 |
| US-20180036333-A9 | AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | FAAH 1214/4885GPR84 225/4885FFAR1 129/4885 |
| US-20130158021-A1 | AMINO ACID-, PEPTIDE-AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF | APLNR, NPPA, ARGLU1 | FAAH 1214/4885GPR84 225/4885FFAR1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.